跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AREXVY - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AREXVY
Authorized
STANDARD
AREXVY
GlaxoSmithKline Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
eaf60d0a363f2887
Company
GlaxoSmithKline Inc
Type
Standard
Approval Details
Approval Id
eaf60d0a363f2887
Drug Approval Canada Name
AREXVY
Product Name
AREXVY
Status
Marketed
Status Date
2023-09-06
Original Market Date
2023-09-06
Din
02540207
Drug Class
Human
Dosage Form
Powder For Suspension
Route Of Administration
Intramuscular
Schedule
Schedule D
Ahfs
80:12.00
Atc Original
J07BX05 RESPIRATORY SYNCYTIAL VIRUS VACCINE
Atc Name
j 07 bx 05
Aig Number
0164921001
Company Name
GlaxoSmithKline Inc
Company Address
800, 100 Milverton Drive, Mississauga, Ontario, Canada, L5R 4H1
Company Detail Path
/organization/glaxosmithkline-inc
Company Information
Pharmaceutical Company Name
GlaxoSmithKline Inc
Country Name
Canada
Province Name
Ontario
City Name
mississauga,ontario,country_ca
Address
800-100 Milverton Dr
Active Ingredients
RESPIRATORY SYNCYTIAL VIRUS PREFUSION F PROTEIN (RSVPREF3)
120 MCG / 0.5 ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
eaf60d0a363f2887
Type
Standard
Back to Health Canada Approvals